Ubs Group Ag In Med Pharmaceuticals Inc. Call Options Transaction History
Ubs Group Ag
- $400 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INM
# of Institutions
16Shares Held
463KCall Options Held
0Put Options Held
0-
Sabby Management, LLC Upper Saddle River, NJ307KShares$73,7365.39% of portfolio
-
Virtu Financial LLC New York, NY86.7KShares$20,8040.0% of portfolio
-
Baader Bank Aktiengesellschaft Unterschleissheim, 2M22.6KShares$5,4260.0% of portfolio
-
Xtx Topco LTD London, X017.8KShares$4,2760.0% of portfolio
-
Hrt Financial LP New York, NY16KShares$3,8390.0% of portfolio
About InMed Pharmaceuticals Inc.
- Ticker INM
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 908,761
- Market Cap $218K
- Description
- InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in precl...